Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy
- PMID: 20071456
- DOI: 10.1677/ERC-09-0253
Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy
Abstract
Resistance to chemotherapy is a major complication in the treatment of advanced breast cancer. Estrogens and prolactin (PRL) are implicated in the pathogenesis of breast cancer but their roles in chemoresistance have been overlooked. A common feature to the two hormones is activation of their receptors by diverse compounds, which mimic or antagonize their actions. The PRL receptor is activated by lactogens (PRL, GH, or placental lactogen) originating from the pituitary, breast, adipose tissue, or the placenta. Estrogen receptors exist in multiple membrane-associated and cytoplasmic forms that can be activated by endogenous estrogens, man-made chemicals, and phytoestrogens. Here, we review evidence that low doses of PRL, estradiol (E(2)), and bisphenol A (BPA) antagonize multiple anticancer drugs that induce cell death by different mechanisms. Focusing on cisplatin, a DNA-damaging drug which is effective in the treatment of many cancer types but not breast cancer, we compare the abilities of PRL, E(2), and BPA to antagonize its cytotoxicity. Whereas PRL acts by activating the glutathione-S-transferase detoxification enzyme, E(2) and BPA act by inducing the antiapoptotic protein Bcl-2. The implications of these findings to patients undergoing chemotherapy are discussed.
Similar articles
-
Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells.J Steroid Biochem Mol Biol. 2004 Jan;88(1):69-77. doi: 10.1016/j.jsbmb.2003.10.008. J Steroid Biochem Mol Biol. 2004. PMID: 15026085
-
Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase.Carcinogenesis. 2009 Aug;30(8):1298-304. doi: 10.1093/carcin/bgp120. Epub 2009 May 14. Carcinogenesis. 2009. PMID: 19443905 Free PMC article.
-
Prolactin activates Stat1 but does not antagonize Stat1 activation and growth inhibition by type I interferons in human breast cancer cells.Cancer Res. 1998 May 1;58(9):1914-9. Cancer Res. 1998. PMID: 9581833
-
Prolactin and the prolactin receptor: new targets of an old hormone.Ann Med. 2004;36(6):414-25. doi: 10.1080/07853890410033892. Ann Med. 2004. PMID: 15513293 Review.
-
The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (review).Oncol Rep. 2002 Jan-Feb;9(1):3-9. Oncol Rep. 2002. PMID: 11748447 Review.
Cited by
-
Prolactin gene expression in primary central nervous system tumors.J Negat Results Biomed. 2013 Jan 14;12(1):4. doi: 10.1186/1477-5751-12-4. J Negat Results Biomed. 2013. PMID: 23317095 Free PMC article.
-
Involvement of miR-106b in tumorigenic actions of both prolactin and estradiol.Oncotarget. 2017 May 30;8(22):36368-36382. doi: 10.18632/oncotarget.16755. Oncotarget. 2017. PMID: 28422740 Free PMC article.
-
Characterization of Δ7/11, a functional prolactin-binding protein.J Mol Endocrinol. 2012 Dec 31;50(1):79-90. doi: 10.1530/JME-12-0201. Print 2013 Feb. J Mol Endocrinol. 2012. PMID: 23048206 Free PMC article.
-
Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor.Trends Endocrinol Metab. 2010 Nov;21(11):691-8. doi: 10.1016/j.tem.2010.08.004. Epub 2010 Sep 16. Trends Endocrinol Metab. 2010. PMID: 20846877 Free PMC article. Review.
-
In vivo evaluation of the potential protective effects of prolactin against damage caused by methylmercury.Braz J Med Biol Res. 2022 Jul 13;55:e11976. doi: 10.1590/1414-431X2022e11976. eCollection 2022. Braz J Med Biol Res. 2022. PMID: 35857996 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
